Effect of Vitamin D Supplementation on Disease Activity (SLEDAI) and Fatigue in Systemic Lupus Erythematosus Patients with Hipovitamin D: an Open Clinical Trial by Rifa’i, A. (Achmad) et al.
Original Article
32 Indonesian Journal of Rheumatology 2016; Vol 8 No.2
Effect of vitamin D supplementation on disease activity 
(SLEDAI) and fatigue in Systemic Lupus Erythematosus 
patients with hipovitamin D: An Open Clinical Trial
Achmad Rifa’i1, Handono Kalim1, Kusworini2, C. Singgih Wahono1
1Division of Rheumatol-
ogy and Immunology-
Department of Internal 
Medicine, University of 
Brawijaya / dr.Saiful An-
war Hospital Malang
2Department of Clinical 
Pathology,University of 
Brawijaya/dr.Saiful Anwar 
Malang
Corespondence : 
Achmad Rifa’i, MD
 Division of Rheumatol-
ogy and Immunology-
Department of Internal 
Medicine
 University of Brawijaya / 
dr.Saiful Anwar Hospital 
Malang, 
dwirifai76@yahoo.co.id, 
Abstract
Background : Low level of vitamin D impact the 
disease activity and the degree of fatigue in SLE 
patients. This study aims to determine the effect of 
vitamin D supplementation on disease activity and 
fatigue condition in Systemic Lupus Erythematosus (SLE) 
patients with hipovitamin D. 
Methods: We performed an open clinical trial. 
Subjects were randomized into two different groups 
(supplementation or placebo) using simple random 
sampling. The treatment group got vitamin D3 softgel/
cholecalciferol 1200 IU/day or 30 mg/day, while the 
control group gotplacebo for 3 months. SLEDAI scores 
and FSS scores were calculated at pre and post 
treatment. 
Results: There were 20 subjectsfor supplementation 
group and 19 subjects  in the placebo group. From this 
study, before and after treatment, we found a significant 
difference of mean level of vitamin D in supplementation 
group (p=0.000), and no significant difference in 
patients with placebo (p=0.427). Moreover, from the 
SLEDAI score analysis, observed a significant difference 
bothin the supplemented group (p=0.000) and the 
placebo group (p=0.006). FSS scores significantly 
different in the supplemented group (p=0.000). In 
correlation test,there was a negative correlation (r=-
0763) between vitamin D level and disease activity 
(SLEDAI), and both showing stastistical significance 
between thepre supplementation (p=0.000) and post 
supplementation (r=-0846; p=0.000). Similarly to the 
FSS scores, there was a meaningfulnegative correlation 
(r=-0.931, p=0.000) between the level of vitamin 
D with FSS scores pre and post supplementation 
(r=-0.911; p= 0.000). Furthermore, there was 
a significant correlation between disease activity 
(SLEDAI) pre supplementation with fatigue condition 
pre supplementation (r=0.846; p = 0.000) and post 
supplementation (r=0.913; p= 0.000). 
Conclusion: The supplementation of vitamin D 1200 IU 
per day in patients with SLE improve disease activity and 
degree of fatigue.
Keywords: vitamin D, disease activity, fatigue, SLE
Background
Systemic Lupus Erythematosus (SLE) is a chronic 
autoimmune disease that affects almost every organ 
in human body. This disease primarily affects women 
in reproductive age with the female: male ratio 8: 
1. Prevalence of SLE has been reportedto be12.2 
per 100,000 population with a high mortality and 
morbidity rate, especially in developing countries. 
Although 5 years survival rate of patients SLE 
has increased to 90% at developing countries, but 
Handono, et al. (2000) showed that SLE patients 
in Indonesia hadlower life expectancy,with only 
70% for 5 years survival rate and 50% for 10 years 
survival rate.1
 SLE interferes the autoregulation of the 
immune system. The role of immune regulation 
in SLE patients is influenced by the level of 
vitamin D,2 it was supported by the results of a 
study, which found anegative correlation between 
vitamin D level and disease activity, degree of 
fatigue, and production of autoantibody.3 Another 
study conducted in Indonesia stated that 71% 
SLEpatients experienced deficiency of vitamin D.4 
This low level of vitamin D may be happened due 
tosun avoidance because of photosensitivity that 
result inless sun exposure.5 Low levelof vitamin 
D in patients with SLEhasimpacted the clinical 
condition of the patient, which would certainly 
affect the disease activity itself.
 Fatigue is a serious problem in SLE patients. 
One study showed that nearly 81% of SLEpatients 
experienced fatigue, 60% of them had lowsleeping 
quality.6 These results were supported by in vivo 
studies in SLE patients which proved that the 
administration of 1,25 (OH)2D3 improved the life 
ofquality of patients, and one of it wasfatique7. The 
presence of fatigue in patients with SLE will lower 
patients’ compliance onthe treatment, and causing 
negative impact on their social life infamily and 
community. Therefore, this study is aimed to 
determine the effect of vitamin D supplementation 
on the disease activity and fatigue condition in SLE 
patients with hypovitaminosis D.
Research Methods
Study Design
This was an open label clinical trial with a control 
(SLE patients that get standard SLE therapeutic 
and plasebo) to assess the effects of vitamin D 
supplementation on disease activity and the degree 
of fatigue in SLE patients with hypovitaminosis 
D. The study was conducted atoutpatient and 
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inpatient settingsin Rheumatology division of the Department 
of Internal Medicine Dr. Saiful Anwar Hospital Malang. 
Research was carried out from January 2013 to December 
2013. The study lasted for 3 months for eachpatient.
Population and Sample Research
Population in this study was SLE patients who sought 
treatment from Internal Medicine Deparment Dr Saiful 
Anwar Hospital within 1 year. Diagnosis was taken based 
on the ACR criteria 1997. Samples were SLE patients who 
had vitamin D deficiency and met the inclusion criteria based 
on the determined time. The subjects were randomized into 
2 different groups (group supplementation or placebo) using 
simple random sampling.
 Inclusion and control criterias were: women with SLE, 
aged 18-43 years old, duration of disease ≤ 1 year, SLEDAI 
scores ≥ 5, experienced hypovitaminosis D, and did not 
taking any medicationcontaining vitamin D (diet containing 
vitamin D was not counted as vitamin D supplementation). 
The exclusion criterias were: patients suffered severe infection 
(sepsis), trauma, liver disease with AST and ALT 2.5 above 
normal, renal disease with GFR≤ 60 (cockrofgault), oliguria 
<400 cc / day, pregnancy, and breastfeeding.
 This study was approved by the Ethics Committee of the 
Faculty Medicine of Brawijaya University/Dr. Saiful Anwar 
Hospital. Informed concent has been obtained from all 
subjects. 
Recruitment Procedures Samples
Patients who met the inclusion and exclusion citerias, 
and agreed to participate were asked to sign the informed 
consent, had initial examination and physical examination. 
SLEDAI scores and FSS score were also evaluated. Then the 
research subjects were supplemented with vitamin D3 softgel/
cholecalciferol 1200 IU/day or 30 mg/ day while the controls 
were given a placebo.
 During the study, patients were routinely followed up in 
Rheumatology Clinic every Monday or Wednesday to monitor 
the side effects of  Vitamin D supplementation and taking the 
next month medication. Supervision of drug consumption 
were done by the patients and their family members who 
were willing to supervise the patient the early days to count 
the number of remaining medicine,in order to measure the 
amount of medicine that had been taken. The monitoring was 
carried out for 3 months. Monitoring of SLEDAI score, FSS 
score as well as vitamin D levels was repeated in the end of the 
study to each sample.
Statistical Analysis
The differences of vitamin D levels before and after 
supplementation of vitamin D were analyzed using paired-
sample t-test, p <0.05 was considered significant. In 
addition,the relationship of disease activity and fatigue 
conditions were analyzed using Pearson correlation test, 
and the statistical analysis was performed  using SPSS for 
Windows 17. 
Result
Characteristics of Research Subjects
The number of patients who met the inclusion criteria and 
exclusion criteria were  20 subjects for treatment groupand 19 
people for placebo group. Characteristics of the patients in this 
study are presented in Table 1. 
Table 1. Characteristics of Subjects
Characteristic Supplementation Placebo P
mean±SD mean±SD
Age (year) 28.25± 6.97 27.26±6.76 0.55
Duration of illness (month) 3.55±1.90 2.74±1.86 0.17
Level of Vitamin D (ng/ml) 23.89± 3.07 26.06±3.71 0.86
SLEDAI 12.65±4.85 10.74±2.75 0.19
Fatigue Severity Score (FSS) 5.41±1.02 4.86±0.77 0.12
Level of ds DNA 226.8±82.1 238.3±65.0 0.68
Level of Calsium (mg/dl) 8.85±0.393 0.898±0.384 0.322
Early Manifestations(%)
•	 Mucocutaneous
•	 Arthritis
•	 Nephritis
•	 Haematology disorder
•	 Serositis
•	 Cerebral 
6 (30 %)
5 (25 %)
8 (40 %)
7 (35%)
3 (15%)
1  (5% )
9 (47 %)
5 (26 %)
4 (21 %)
8 (42%)
2 (11%)
0 ( 0 %)
Treatment (%)
•	 non immunosupressant
•	 Azathioprin
•	 Cyclophosphamid
•	 Methyl Mecofenolat         
(MMF) 
•	 Chloroquin
2 (10 %)
5 (25 %)
2 (10 %)
6 (30 %)
5 (25 %)
3 (15.8 %)
5  (26.3%)
1 (5.30%)
3 (15.8 %)
7 (36.8 %)
Vitamin D Level
The difference levelof vitamin D before and after 
supplementation in control and intervention groups are 
presented in Figure 1.
Figure 1 Comparison level of vitamin D pre and post 
supplementation. 
Oral vitamin D supplementation significantly increase the 
vitamin D level in intervention group, as shown above. 
There was significant difference of vitamin D level between 
pre and post vitamin D supplementation in SLEpatients 
(p=0.000). While in group of patients with placebo, there 
was no significant difference between pre and post placebo 
administration (p=0.658).The mean of delta vitamin D level 
before and after intervention were 6.55 ± 0.09 ng/ml in 
experimental group and only 0.17 ± 1.63 ng/ml in control group. 
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SLEDAI Score
This study showed that SLEDAI score before and after 
supplementation had a significant difference, in both group 
receiving oral vitamin D and oral placebo. The experimental 
group showed a decrease in the average value of SLEDAI 
from 12.65±4.85 to 6.20±2.67 with a mean  decreased 6.45 ± 
2.18. Whereas, the placebo group showed a decrease average 
value of SLEDAI  from 10.74±2.75 to 9.68±2.26 with the 
mean of decrease 1.06±0.49 .
Figure 2 Comparison of the decreased SLEDAI score in patients 
post supplementation versus pre supplementation. 
The SLEDAI score in post supplementation was lower than pre 
supplementation group (p=0.000). Same as supplementation 
group, SLEDAI score in post placebo tend to be lower than 
pre placebo group (p= 0.006).
There was a significant decrease of SLEDAI score in both 
groups after 3 months trial.
FSS value changes before and after supplementation
This study showed that FSS score before and after 
supplementation had a difference, both in the vitamin 
D supplementation and the placebo group. Vitamin D 
supplementation group showed a significant decreasing of the 
average value of FSS score with the mean decrease was 2.25 
± 0.73. It means there was a fatigue improvements in group 
of SLE patients receiving oral vitamin D supplementation. 
In the placebo group, the decrease was just slightly, with 
average decrease value only  -0.005 ± 0.62, and no statistical 
difference (p>0.05) were found. The FSS score before and 
after oral vitamin D supplementation can be seen in Figure 3.
Figure 3 Comparison of FSS score pre and post supplementation. 
There was a significant difference between the mean  FSS 
score pre  and post vitamin D supplementation in SLE patients 
(p=0.000). While the average FSS score between patients 
pre and post placebo in SLE patients showed no significant 
difference (p=0.971).
 The significant improvements were seen in all aspect of 
FSS questions. The higher significant changes (p<0.001) were 
seenin: fatigue affects motivation (P-1), physical exercise as 
fatigue precipitator ( P-2), easy experience of fatigue (P-3), 
patients often have problems with fatigue (P-5), fatigue affects 
the physical endurance (P-6), and fatigue as one of the main 
complained (P-8). While the physical activity disorder (P-4), 
the fatigue affects the duties and responsibilities of the patient 
(P-7),  and the fatigue effect on the environment, family life 
and social life (P-9) have p value <0.05.Those result shown at 
Table 2.
Table 2 The Result of Various Parameters in FSS Score
Item Pre Supple-
mentation
Post Supple-
mentation
P
Mean ±SD Mean ±SD
Effect on  Motivation (P-1) 5.00 ± 1.12 2.95 ± 1.23 .000
Physical exercise as fatigue 
precipitator ( P-2)
4.95 ± 1.19 3.20 ± 1.47 .000
Easy experience of fatigue (P-3) 5.30 ± 1.26 3.20 ± 1.51 .000
Physical activity disorder
(P-4)
5.45 ± 1.15 3.10 ± 1.33 .011
Patients often have problems 
with fatigue (P-5)
5.70 ± 1.26 3.15 ± 1.42 .000
Fatigue affects the physical 
endurance (P-6)
5.40 ± 1.43 3.25 ± 1.48 .000
Fatigue affects the duties and 
responsibilities of the patient 
(P-7)
5.70 ± 1.03 3.25 ± 1.52 .001
Fatigue as one of the main 
complained (P-8)
5.60 ± 1.05 3.25 ± 1.48 .000
Fatigue effect on the enviroment, 
family life and social life (P-9)
5.85 ± 1.27 3.15 ± 1.42 .003
Significant if p < 0.05
Correlation of vitamin D level with various parameters
The correlation of disease activity (SLEDAI) between the 
supplemented group and the placebo group analyzed by 
Pearson’s correlation test. The aim of correlation test was 
to determine the relationship between disease activity with 
vitamin D level before and after treatment. 
Figure 4 Correlation between level of vitamin D and SLEDAI  Score 
A. Before Vitamin D supplementation; B. After Vitamin D 
suplementation
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Correlation test showed an inverse relationship between 
vitamin D level and disease activity (SLEDAI) before 
supplementation (p=0.000; r= -0.763). There was a strong 
relationship between vitamin D level and disease activity 
(SLEDAI) after supplementation p=-0.846. Negative values 
indicated an inverse relationship, means when the level of 
vitamin D escalates there will be a decrease in disease activity 
(SLEDAI) .
Figure 5 Correlation between level of vitamin D and FSS score
A. Before Vitamin D supplementation; B. After Vitamin D 
suplementation
This study showed association between vitamin D level 
with the Fatigue Severity Scale (FSS), before and after the 
supplementation. There was an inverse relationship between 
vitamin D level with FSS before supplementation (p=0.000; 
r= -0.931), and also vitamin D levels with FSS after 
supplementation (p=0.000; r=-0.911).
Figure 6 Correlation between SLEDAI score and FSS Score 
    
A. Before Vitamin D supplementation; B. After Vitamin D 
supplementation
Correlation analysis showed a strong relationship between 
disease activity (SLEDAI) and fatigue condition before 
getting supplementation (p=0.000; r=0.846). There was also 
strong a relationship between SLEDAI score with FSS after 
supplementation (p=0.000, r =0.913).
Discussion
Supplementation of cholecalciferol 1200 IU for 3 months gave 
a positive effect on the increasing levels of 25(OH)D serum. 
This showed by  significant elevation levels of 25(OH)D in 
the supplemented group, with average rise 6.55 ± 1.27 ng/ml 
from the initial baseline. The increasing levels of 25(OH)D 
serum slightly lower than the previous study, which resulted 
an increase vitamin D level approximately 10ng/ml with 
cholecalciferol 1000 IU per day for 3-4 months. Moreover, 
another study reported an increase level of 25(OH)D to 40ng/
ml with 3000IU supplementation of cholecalciferol for three 
months. 9 However, the change of 25(OH) D level does not 
always have linear correlation with the supplementation of 
vitamin D, which mean the same dose supplementation of 
vitamin D does not always increase the same value of 25(OH) 
D level in the blood. It is really depend on each individual 
characteristic.9 Similar condition also occured in study 
conducted by Irastorza, where the elevated levels of 25(OH)
D ranged from 3.1 ng/ml, with a median dose of 600 IU (dose 
range of 400-1200 IU per day).7
 Patients with SLE often develop photosensitivity, 
malar rash, and discoid rash on his limbs. Therefore, there 
is a tendency for SLE patients to avoid sunlight and use 
photoprotection.10 Some literature stated that in healthy 
condition, accidental sun exposure in the face and hands is 
“enough” for fulfilling the vitamin D requirement ranging 
from 5-10 mg (200-400 IU) of vitamin D. Whereas exposure 
on 5% skin will produce average 35 nmol/L 25 (OH) D. 
Contribution of sunlight to produce vitamin D in the SLE 
patient is relatively low, and would even be lower if they used 
sunscreen necessarily. A sunscreen with an SPF of 15 will 
absorb 99% of UVB radiation, and, thus, when sunscreen is 
applied, it will reduce 99%  the synthesis of vitamin D3 in 
the skin.11,12 In addition, the presence of renal insufficiency, 
caused by chronic use of hidrokloroquin and glucocorticoids 
in SLE patients can also interfere the metabolism of vitamin 
D.10
 Target levels of 25(OH)D in SLE patients is 30 ng/ml. In 
this level, the risk of morbidity caused by hypovitaminosis D 
will be greatly reduced. In this study, we found that giving 3 
month oral vitamin D supplementation would result the 50% 
of patients achieved the target level with 25 (OH) D value 
greater than or equal to 30 ng/ml. There is no evidence of 
additional benefits in 25(OH)D levels more than40 ng/ml.13
 In this study, there was an inverse relationship between 
SLEDAI and FSS score with vitamin D level in both groups. 
However, the result of supplementation group greater than 
the placebo group with a strong correlation coefficient. The 
relationship between disease activity with vitamin D levels 
in SLE patients also demonstrated in a study conducted by 
Tolaza which showed a negative correlation between the 
levels of 25(OH)D3 with disease activity score in SLE patients, 
evaluated usingby ECLAM and SLEDAI. Similar result also 
found in research conducted by Borba (2009).14  In Thudi, et 
al. (2008) study, involve 37 female SLE patients found that 
20% of patients who developed clinical manifestation and 
immunology had lower level of 25(OH)D (<47.7 nmol/L).15 
Patients with low levels of vitamin D will significantly 
have higher disease activity compared to SLE patients with 
normal vitamin D level (p <0.003).15 Similar results were 
also obtained in study conducted by Petri, et al (2013), who 
stated that an increased of 20 ng/ml 25 (OH) D level would 
decreased disease activity in 21% patients with high disease 
activity score.13
 Low level of vitamin D is one of the indicator  of the ongoing 
inflammatory process. Inflammation potentially increases the 
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metabolism of vitamin D. This suggests that patients with 
high SLEDAI scores may get some benefits from vitamin D 
supplementation. Moreover, supplementing vitamin D can 
improve immunological abnormalities of patients with SLE, 
and automatically will improve the clinical manifestations 
of SLE.10 The symptoms of vitamin D deficiency is still 
unclear. But some symptoms may arise as a result of vitamin 
D deficiency include: fatigue, musculoskeletal disorders (such 
as muscle pain found in the entire body, muscle stiffness), joint 
pain, weight gain, high blood pressure, sleep disturbances, 
impaired concentration , headache, constipation or diarrhea.17 
This study showed before getting any treatment most of 
subjects experienced severe fatigue conditions with mean 
FSS score more than 4. After getting 3 months treatment, 
there was a significant decreased of FSS scores in the 
supplementation group (compared placebo group) which mean 
as an improvement of the fatigue condition of the patient.One 
study reported that nearly 81% of SLE patients experienced 
fatigue 6, and showed an inverse relationship between level of 
vitamin D with the degree of fatigue on SLE patient. It is also 
supported by the results study conducted by Irastorza where 
the improvement level of vitamin D through supplementation 
1,25(OH)2D3 also improved the condition of fatigue in SLE 
patients. 7
 In a review article that included 22 studies with a total 
sample of 3670 patients with musculoskeletal pain and 
fatigue, stated that 48% of them had a significant vitamin D 
deficiency, and after improvement of vitamin D levels, subjects 
experienced some improvement in the degree of pain and 
muscle weakness, as well as in physical function.18  Muscle 
weakness has long been associated with vitamin D deficiency. 
This happened because there is a vitamin D receptor in skeletal 
muscle. Hypovitaminosis Dhas been associated with proximal 
muscle weakness, decreased body stability, and increased 
risk of falling.12 Treatment with vitamin D improves muscle 
function among patients with hypovitaminosis by increasing 
cross-sectional area of  fast-twitch type II A fibers and increase 
muscle strength of proximal muscle.19
 Fatigue severity scale (FSS) has been recommended by 
ACR 2007 at the Ad Hoc Committee on Systemic Lupus 
Erythematosus response criteria for fatigue to assess the 
fatigue condition in SLE patients with highvalidity and 
reliability. FSS has been translated into several languages.20 
The FSS consists of nine questions with a range of values 
between 1 and 7 on each item question, with score>4 shows 
a severe condition of fatigue.20 Nine items from FSS question 
refers to a variety of conditions that occur in patients who 
experienced SLE fatigue. These conditions include: physical 
functioning, vitality, emotional, social, and metal health.21
 In this study we found that vitamin D supplementation 
improved the overall FSS conditions, such as the physical 
functioning, vitality, emotional, social, and mental health, 
which indicates the presence of significant changes (p <0.05) 
at 9 item questions in FSS.This condition is consistent with 
the results from research conducted by Lorentzen (2014) 
who found SLE patients with fatigue will cause a decrease in 
physical, social and mental function.22
This study also showed there was a significant association 
between disease activity and fatigue. Previous studies reported 
that SLE patient with severe fatigue had higher disease score 
activity. However, the main clinical features of higher disease 
activity is not the fatique, but the significant decreased 
of physical distress (headache, anxiety, musculosceletal 
disorder, stomachache, fever, and weight loss).23 Therefore, 
the relationship between fatigue and disease activity SLE is 
still controversial. There are some inconsistent results of the 
fatigue relation with SLE disease activity in previous studies. 
Antoni, et al.(2007) metaanalysis study, identified 34 studies 
published in the last 40 years. From the studies, there were 10 
studies that evaluated the correlation between disease activity 
and fatigue in SLE patients. The 8 studies showed a significant 
relationship between disease activity with fatigue condition in 
SLE patients, but the other two did not.6,24-30 Different results 
obtained from Wang, et al.(1998 ), which found no relationship 
between disease activity with fatigue.31
 In this study, there was no adverse effects found in the 
supplemented group. According to the European Commission’s 
Scientific Committee on Food (SFC), tolerable upper intake 
levels (UL) of vitamin D is 50 mcg/day equivalent to 2000 
IU of vitamin D3, while the United Kingdom Expert Group 
on Vitamins and minerals (EVM) set a dose of 25 mg/day. 
Maximum NOAEL (no observed adverse effect levels) of 
vitamin D is 250 mcg/day with toxicity effects may include 
hypercalcemia, hypertension, nausea, vomiting and even 
could interfere renal function.32Other literature mentioned that 
toxicity will occur if the patient is taking more than10,000 IU 
of vitamin D per day for months to years. Until now there is no 
literature available explaining the toxicity of cholecalciferol 
consumption less than 10,000 IU per day.9 Toxicity that occurs 
as a result of the increase in calcium levels are considered as 
secondary toxicity. This toxicity occurs gradually until levels 
of 25 (OH) D exceeds 150 ng/ml.32
 In this research we evaluated the calcium levels both 
pre- and post-treatment in the supplementation group and the 
placebo group, at the end calcium results were within normal 
range.
 
Conclusion
The supplementation of vitamin D 1200 IU per day in SLE 
patients improved disease activity and fatigue conditions.
Research weakness
The weaknesses of this study are the number of subjects 
enrolled in this study was the minimal sample required and 
we did not use a double blind study. 
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